Real Research, Real Results. Together We Can Cure Cancer.
The Sbarro Health Research Organization (SHRO) is a nonprofit charity committed to funding excellence in basic genetic research to cure and diagnose cancer, cardiovascular diseases, diabetes and other chronic illnesses and to foster the training of young doctors in a spirit of professionalism and humanism. In 1993, Antonio Giordano, M.D., Ph.D., founded the Sbarro Institute with a generous donation from Mario Sbarro, the Founder of the Sbarro restaurant chain, following Dr. Giordano’s discovery of the tumor suppressor gene pRb2. Initially named the Sbarro Institute, the research center was located at Thomas Jefferson University, where Dr. Giordano was a professor.
Message from Dr. Antonio Giordano – Founder of SHRO
“Think of genetic research as language. We have identified the words; now we are constructing the dictionary and learning the rules of grammar. Our task is to continue assembling the dictionary and perhaps the construction of a few grammatically accurate sentences. The goal is to eventually add new chapters to the novel of life”
Editorial by Prof. Philip Landrigan, Director of the Global Public Health Programme, published in the second issue of Annals of…Read More
Newswise press release — Oncology researchers using Virtual Reality (VR) in the treatment of cancer patients have published a review of the…Read More
Newswise — A group of researchers including Antonio Giordano, M.D., Ph.D., Director and Founder of the Sbarro Health Research Organization…Read More
Original Newswise post There is a growing awareness that the design of clinical trials can be misleading and provide evidence…Read More
“If I have seen further it is by standing on the shoulders of Giants” – Sir Isaac Newton (in…Read More
“It is not a problem connected to “the Sputnik V” vaccine itself,” argues Prof. Enrico Bucci, adjunct professor in the…Read More
Newswise — WASHINGTON, D.C. May 19, 2021—At the prestigious setting of Villa Firenze, the Italian Embassy in Washington, DC, on…Read More
In patients with non-small cell Lung Cancer (NSCLC), the presence of either high chronic inflammation, or procalcitonin levels in the…Read More
Scientists use engineered protein coating that binds to receptors on the surface of corneal cells to improve drug uptake. The…Read More